Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Kim, Hae Rim ^a   Kim, Kyoung Woon ^b   Jung, Hong Geun ^a   Yoon, Kwang Sup ^a   Oh, Hye Jwa ^c   Cho, Mi La ^c   Lee, Sang Heon ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; JANUS KINASE 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR AP 1; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE DESTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST LIKE SYNOVIOCYTE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIAL FLUID LEVEL; SYNOVIOCYTE; WESTERN BLOTTING; BIOSYNTHESIS; COCULTURE; FIBROBLAST; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; OSTEOLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; UPREGULATION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; BONE RESORPTION; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MIDDLE AGED; OSTEOCLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; UP-REGULATION;

EID: 79952501967     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3279     Document Type: Article

References (44)

1. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999, 42:1601-1608. 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B, 10446857.
2. Morand EF, Bucala R, Leech M. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. Arthritis Rheum 2003, 48:291-299. 10.1002/art.10728, 12571836.
3. Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D, Sandison A, Seiki M, Nanchahal J, Nagase H, Itoh Y. Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 2009, 60:686-697. 10.1002/art.24331, 2819053, 19248098.
4. Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK, Santos LL, Morand EF, David JR, Koch AE. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R132. 10.1186/ar2021, 1779381, 16872482.
5. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000, 59:455-461. 10.1136/ard.59.6.455, 1753174, 10834863.
6. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000, 275:444-450. 10.1074/jbc.275.1.444, 10617637.
7. Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S, Minami A. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 2002, 277:7865-7874. 10.1074/jbc.M106020200, 11751895.
8. Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J, Kim HY. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007, 34:927-936.
9. Carli C, Metz CN, Al-Abed Y, Naccache PH, Akoum A. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways. Endocrinology 2009, 150:3128-3137. 10.1210/en.2008-1088, 2703510, 19299454.
10. Sampey AV, Hall PH, Mitchell RA, Metz CN, Morand EF. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 2001, 44:1273-1280. 10.1002/1529-0131(200106)44:6<1273::AID-ART219>3.0.CO;2-8, 11407686.
11. Oshima S, Onodera S, Amizuka N, Li M, Irie K, Watanabe S, Koyama Y, Nishihira J, Yasuda K, Minami A. Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett 2006, 580:1251-1256. 10.1016/j.febslet.2006.01.038, 16442103.
12. Onodera S, Sasaki S, Ohshima S, Amizuka N, Li M, Udagawa N, Irie K, Nishihira J, Koyama Y, Shiraishi A, Tohyama H, Yasuda K. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 2006, 21:876-885. 10.1359/jbmr.060310, 16753018.
13. Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R, Kuchel GA, Lee SK. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone 2009, 45:640-649. 10.1016/j.bone.2009.06.028, 19591967.
14. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005, 52:3020-3029. 10.1002/art.21285, 16200611.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
16. Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, Kim JS, Park SH, Lee SH, Kim HY. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 2007, 56:1076-1086. 10.1002/art.22439, 17393416.
17. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005, 52:2656-2665. 10.1002/art.21273, 16142732.
18. Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC, Mountz JD. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 2005, 52:3257-3268. 10.1002/art.21354, 16200600.
19. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323. 10.1038/16852, 9950424.
20. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602. 10.1073/pnas.95.7.3597, 19881, 9520411.
21. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Athanasou NA. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 2001, 28:261-267. 10.1016/S8756-3282(00)00453-1, 11248655.
22. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987, 1:1108-1111. 10.1016/S0140-6736(87)91672-2, 2883443.
23. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, Genant HK, Gofton JP, Goodman N, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?. Arthritis Rheum 1985, 28:1326-1335. 10.1002/art.1780281203, 4084327.
24. Schett G. Erosive arthritis. Arthritis Res Ther 2007, 9(Suppl 1):S2. 10.1186/ar2166, 1924517, 17634141.
25. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132. 10.1093/rheumatology/39.2.122, 10725061.
26. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009, 60:1242-1249. 10.1002/art.24433, 19404938.
27. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001, 44:2009-2017. 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L, 11592361.
28. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986, 29:494-500. 10.1002/art.1780290406, 3707627.
29. Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2002, 14:406-410. 10.1097/00002281-200207000-00013, 12118176.
30. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. 1858257, 9546355.
31. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000, 43:821-826. 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T, 10765926.
32. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984, 27:968-975. 10.1002/art.1780270902, 6236824.
33. Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, Bromme D, Gay S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998, 25:1887-1894.
34. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699. 10.1016/S0002-9440(10)63016-7, 1867076, 11696430.
35. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488. 10.1172/JCI11176, 387259, 11120755.
36. Lacey D, Sampey A, Mitchell R, Bucala R, Santos L, Leech M, Morand E. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003, 48:103-109. 10.1002/art.10733, 12528110.
37. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753. 10.1002/art.10388, 12124857.
38. Oelzner P, Franke S, Lehmann G, Eidner T, Muller A, Wolf G, Hein G. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 2007, 26:2127-2135. 10.1007/s10067-007-0639-5, 17541498.
39. Santos LL, Lacey D, Yang Y, Leech M, Morand EF. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004, 31:1038-1043.
40. Onodera S, Nishihira J, Koyama Y, Majima T, Aoki Y, Ichiyama H, Ishibashi T, Minami A. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta. Arthritis Rheum 2004, 50:1437-1447. 10.1002/art.20190, 15146413.
41. Kim HR, Park MK, Cho ML, Kim KW, Oh HJ, Park JS, Heo YM, Lee SH, Kim HY, Park SH. Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinase-dependent signaling pathway. Korean J Intern Med 2010, 25:317-326. 10.3904/kjim.2010.25.3.317, 2932946, 20830230.
42. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010, 363:1303-1312. 10.1056/NEJMoa1000500, 20879879.
43. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009, 60:1232-1241. 10.1002/art.24485, 19404957.
44. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60:1895-1905. 10.1002/art.24567, 19565475.